How can better data improve decision-making in a curable but nuanced disease like testicular cancer? This episode explores how large language models can turn unstructured clinical notes into actionable insights, helping clinicians refine treatment selection, understand practice variation and balance cure with long-term toxicity management.

Is there a role for earlier integration of lutetium PSMA therapy in mCRPC management? Emerging evidence supports its use in the pre-taxane setting, prompting a shift in sequencing decisions. This episode outlines patient selection, PSMA imaging requirements and how to balance disease aggressiveness, tolerability and real-world considerations when choosing between lutetium and chemotherapy.

As cancer care becomes increasingly personalized, treatment deescalation is emerging as a key strategy to balance efficacy with quality of life. In this episode of Cancer Advances, Jame Abraham, MD, Enterprise Chair of Hematology and Medical Oncology at Cleveland Clinic, discusses how clinicians are rethinking dose intensity, duration and therapeutic selection across disease settings. Learn how evolving evidence, patient preferences and emerging technologies like AI are shaping treatment decisions and redefining standards of care.